Showing results (31-40 of 89) with videos related to

Sort By:
Pageof 9
Annales De Dermatologie Et De Venereologie|October 22, 2008
[Eruptive nevi associated with sorafenib treatment]M Bennani-Lahlou, C Mateus, B Escudier, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|April 8, 2017
[Radiation-induced bronchiolitis obliterans with organizing pneumonia]J Ducray, S Vignot, A Lacout, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Risk factors for brain relapse in patients with metastatic breast cancerK Slimane, F Andre, S Delaloge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2009
Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine featuresY Loriot, C Massard, M Gross-Goupil, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 28, 2012
[Oligometastatic bone disease. Can limited metastatic bone disease be cured? Is there room for local ablative treatments?]J Thariat, A Leysalle, S Vignot, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|July 4, 2012
Nanoporous surface wetting behavior: the line tension influenceV Raspal, K O Awitor, C Massard, et al.
The British Journal of Dermatology|May 27, 2009
Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitorsA Osio, C Mateus, J-C Soria, et al.
Oncogene|April 19, 2006
hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathwayC Massard, Y Zermati, A-L Pauleau, et al.
Medical Oncology (Northwood, London, England)|September 28, 2011
GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinomaJean-Philippe Spano, Y Vano, S Vignot, et al.
Bulletin Du Cancer|January 12, 2011
[Following communications made at American Society of Clinical Oncology 2010, what will change our practice? The point of view of the editorial board of Bulletin du Cancer]T André, M Wislez, A Goncalves, et al.
Pageof 9